RE:RE:Street perception of CeaproMore gaslighting and strawman arguments;
At the end of the day the company as judged by the stock market indicates little faith in monetizing PGX in the near future
As for the compounded return, I'll give Gilles credit for taking the company out of what could have been bankruptcy or delisting, low base to start at, and getting PGX to where it is, but a more agressive timeline and transparency is what others are looking for, all except you
prophetoffacts wrote: Ciao wrote: I'll answer my own question with an opinion from someone else;
"I asked my friend at the CIBC WG about it. He said he knew about it but not interested as they have been around for long without being overly successful. It seems the main concern seems to be the lingering business and lack of business aggressiveness..."
Does your friend have an over 23% compound annual return going on the last nine years? CZO's stock is up over 23% compounded per year in the going on nine years since Gilles has been President and CEO. That is very successful. Sales for the base business have grown at a double digit compound annual rate. CZO has a list of gold plate companies using its products. It has moved out of the business incubator into its own state-of-the-art facility certified. CZO is profitable with growing cash. In addition to the successful base business CZO is aggressive enough to go after a mind-blowing dream in PGX. PGX has progressed from a mere idea in a lab, to pilot scale production, to proof of concept for numerous use applications with important acedemics, to its master piece PGX-YBG. Progress has occurred in the context of ongoing talks with industry. The first PGX product is also in a human clinical trial at the prestigious Montreal Heart Institute with results expected this year. Important researchers in their field from Dr. Kjetil Ask, to Dr. Todd Hoare have also endorsed PGX along with the Canadian Government through various funding. The PGX dream is closer to the goal line than ever and stronger than ever with PGX-YBG. There could be two human clinical trials this year for PGX and then there is avenanthramide. CZO's incredibly ambitious goal of simultaneously growing the base business as it transitions to a successful biopharma has never been more palpable. This is amazing work!